NASDAQ
APLT

Applied Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Applied Therapeutics Inc Stock Price

Vitals

Today's Low:
$1.59
Today's High:
$1.79
Open Price:
$1.79
52W Low:
$0.5
52W High:
$2.73
Prev. Close:
$1.7
Volume:
418361

Company Statistics

Market Cap.:
$47.58 million
Book Value:
0.2
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-64.98%
Return on Equity TTM:
-197.73%

Company Profile

Applied Therapeutics Inc had its IPO on 2019-05-14 under the ticker symbol APLT.

The company operates in the Healthcare sector and Biotechnology industry. Applied Therapeutics Inc has a staff strength of 26 employees.

Stock update

Shares of Applied Therapeutics Inc opened at $1.79 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.59 - $1.79, and closed at $1.6.

This is a -5.88% slip from the previous day's closing price.

A total volume of 418,361 shares were traded at the close of the day’s session.

In the last one week, shares of Applied Therapeutics Inc have increased by +22.14%.

Applied Therapeutics Inc's Key Ratios

Applied Therapeutics Inc has a market cap of $47.58 million, indicating a price to book ratio of 4.2194 and a price to sales ratio of 0.

In the last 12-months Applied Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Applied Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Applied Therapeutics Inc’s operating margin was 0% while its return on assets stood at -64.98% with a return of equity of -197.73%.

In Q3, Applied Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Applied Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Applied Therapeutics Inc’s profitability.

Applied Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0462. Its price to sales ratio in the trailing 12-months stood at 0.

Applied Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$56.68 million
Total Liabilities
$46.51 million
Operating Cash Flow
$5.02 million
Capital Expenditure
$0
Dividend Payout Ratio
0%

Applied Therapeutics Inc ended 2024 with $56.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $56.68 million while shareholder equity stood at $9.63 million.

Applied Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $46.51 million in other current liabilities, 5000.00 in common stock, $-334394000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40.39 million and cash and short-term investments were $47.38 million. The company’s total short-term debt was $470,000 while long-term debt stood at $0.

Applied Therapeutics Inc’s total current assets stands at $55.51 million while long-term investments were $0 and short-term investments were $6.99 million. Its net receivables were $276000.00 compared to accounts payable of $6.97 million and inventory worth $0.

In 2024, Applied Therapeutics Inc's operating cash flow was $5.02 million while its capital expenditure stood at $0.

Comparatively, Applied Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.6
52-Week High
$2.73
52-Week Low
$0.5
Analyst Target Price
$15

Applied Therapeutics Inc stock is currently trading at $1.6 per share. It touched a 52-week high of $2.73 and a 52-week low of $2.73. Analysts tracking the stock have a 12-month average target price of $15.

Its 50-day moving average was $1.47 and 200-day moving average was $1.2 The short ratio stood at 2.55 indicating a short percent outstanding of 0%.

Around 1655.7% of the company’s stock are held by insiders while 6890.8% are held by institutions.

Frequently Asked Questions About Applied Therapeutics Inc

The stock symbol (also called stock or share ticker) of Applied Therapeutics Inc is APLT

The IPO of Applied Therapeutics Inc took place on 2019-05-14

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$100.05
-10.45
-9.46%
$119
1
+0.85%
$529.2
-35.5
-6.29%
$20.5
0.19
+0.94%
$16.6
-1.88
-10.17%
Megasoft Limited (MEGASOFT)
$48
-2.43
-4.82%
ULTRATECH CEMENT LTD. (ULTRACEMCO)
$8577.55
117.8
+1.39%
$763.3
-17.45
-2.24%
$470.12
-1.39
-0.29%
$12.57
-0.04
-0.32%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Address

545 Fifth Avenue, New York, NY, United States, 10017